Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.31 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL100765 | 0.68 | HPGDS (0.46) | HPGDSLTA4HCHRNA7CHRNA10CHRNA9 | |
| SCHEMBL1429349 | 0.68 | KDM4A (0.39) | HPGDSLTA4H | |
| SCHEMBL221943 | 0.67 | HPGDS (0.33) | HPGDSLTA4H | |
| SCHEMBL970056 | 0.67 | KMT2A (0.37) | HPGDSLTA4H | |
| SCHEMBL549435 | 0.65 | MAPT (0.50) | — | |
| SCHEMBL1521933 | 0.65 | HPGDS (0.36) | HPGDSLTA4H | |
| SCHEMBL2762962 | 0.65 | HPGDS (0.33) | HPGDSLTA4H | |
| SCHEMBL9454155 | 0.65 | HPGDS (0.40) | HPGDSLTA4HCHRNA7CHRNA10CHRNA9 | |
| SCHEMBL15600919 | 0.64 | KDM4A (0.43) | — | |
| SCHEMBL17701183 | 0.64 | HPGDS (0.39) | HPGDSLTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2964644-A1 | PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | Amgen Inc. (US) | 2016-01-13 | — | — | EP | claimed |
| WO-2014138484-A1 | PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2014-09-12 | — | — | WO | claimed |
| US-7645764-B2 | Kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC (US) | 2010-01-12 | — | — | US | claimed |
| US-7550494-B2 | Small molecules useful in the treatment of inflammatory disease | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-06-23 | — | — | US | claimed |
| US-20090131370-A1 | Novel Nucleoside Derivatives | METABASIS THERAPEUTICS , INC. (US) | 2009-05-21 | — | — | US | claimed |
| EP-1216247-B1 | IMIDAZOIMIDAZOLES AND TRIAZOLES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMA (US) | 2008-11-05 | — | — | EP | claimed |
| US-20080249029-A1 | Administering (S)-N-Methyl-D-phenylalanyl-N-[4-[(aminoiminomethyl)aminol-1-(2-benzothiazolylcarbonyl)butyl-L-prolinamide as a protease activated receptor-2 modulator | SHAPIRO STANLEY S | 2008-10-09 | — | — | US | claimed |
| EP-1556384-B1 | PYRIMIDO COMPOUNDS HAVING ANTIPROLIFERATIVE ACTIVITY | HOFFMANN LA ROCHE (CH) | 2008-02-20 | — | — | EP | claimed |
| EP-1242426-B1 | GAMMA-HYDROXY-2-(FLUOROALKYLAMINOCARBONYL)-1-PIPERAZINEPENTANAMIDES AS HIV PROTEASE INHIBITORS | MERCK & CO INC (US) | 2007-10-31 | — | — | EP | claimed |
| US-20070219197-A1 | Pyridyl alkene and pyridyl alkine- acid amides as cytostatics and immuno-suppressives | ASTELLAS PHARMA GMBH (DE) | 2007-09-20 | — | — | US | claimed |
| EP-1216247-A1 | IMIDAZOIMIDAZOLES AND TRIAZOLES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2002-06-26 | — | — | EP | claimed |
| EP-1194427-A1 | THIOPHENE-ETHYL THIOUREA COMPOUNDS AND USE IN THE TREATMENT OF HIV | Parker Hughes Institute (US) | 2002-04-10 | — | — | EP | claimed |
| US-6313117-B1 | TREATING AUTOIMMUNE DISORDERS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2001-11-06 | — | — | US | claimed |
| WO-2001032648-A1 | NOVEL CYCLOPROPANES AS CGRP ANTAGONISTS, MEDICAMENTS CONTAINING SAID COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-05-10 | — | — | WO | claimed |
| WO-2001007440-A1 | IMIDAZOIMIDAZOLES AND TRIAZOLES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2001-02-01 | — | — | WO | claimed |
| WO-2000078755-A1 | THIOPHENE-ETHYL THIOUREA COMPOUNDS AND USE IN THE TREATMENT OF HIV | PARKER HUGHES INSTITUTE (US) | 2000-12-28 | — | — | WO | claimed |
| EP-0799205-B1 | 1,4,4-(TRISUBSTITUTED)CYCLOHEX-1-ENE DERIVATIVES AS PDE IV- AND TNF-INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 1999-09-08 | — | — | EP | claimed |
| US-5002942-A | Calcium channel blockers for cardiovascular disorders | SANKYO COMPANY, LIMITED (JP) | 1991-03-26 | — | — | US | claimed |
| US-4795755-A | ANTISECRETORY, ANTIULCER AGENTS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-01-03 | — | — | US | claimed |
| EP-0008277-A1 | Benzopyrano derivatives, pharmaceutical compositions containing them and processes for preparing the compounds and compositions | Technobiotic Ltd. (CH) | 1980-02-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249029-A1 | Administering (S)-N-Methyl-D-phenylalanyl-N-[4-[(aminoiminomethyl)aminol-1-(2-benzothiazolylcarbonyl)butyl-L-prolinamide as a protease activated receptor-2 modulator | MC1R, F2RL1, F2R | HPGDS 681/4885LTA4H 407/4885CHRNA7 2391/4885 |
| US-20070219197-A1 | Pyridyl alkene and pyridyl alkine- acid amides as cytostatics and immuno-suppressives | NFATC1, PDCD1, ACIN1 | HPGDS 96/4885LTA4H 967/4885CHRNA7 3150/4885 |
| US-20090131370-A1 | Novel Nucleoside Derivatives | SLC29A1, SLC29A2, PNP | HPGDS 1635/4885LTA4H 3359/4885CHRNA7 4555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.